Aribio Usa
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.aribiousa.comRevenue
<$5 MillionIndustry
About Aribio Usa
Aribio Usa Org Chart
Is Aribio Usa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Aribio Usa is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Aribio Usa has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Aribio Usa launches new products
Funding: Get notified immidiatlly once Aribio Usa has new funding data
Aribio Usa, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Aribio Usa had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Aribio Usa
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Aribio Usa recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Aribio Usa
Compare insights from companies similar to Aribio Usa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aribio Usa is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aribio Usa is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aribio Usa.
Aribio Usa Tech Stack
A closer look at the technologies used by Aribio Usa
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aribio Usa
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.... Read More